Satter Amends Aileron Therapeutics 13D Filing

TL;DR

Satter updated their Aileron Therapeutics filing on 3/5. Watch for changes.

AI Summary

Muneer A. Satter, through Satter Investment Management, LLC, has amended their Schedule 13D filing for Aileron Therapeutics, Inc. on March 5, 2024. The filing indicates a change in beneficial ownership, though specific new holdings or changes in percentage are not detailed in this excerpt. Satter's address is listed as c/o Satter Investment Management, LLC in Chicago, IL.

Why It Matters

This amendment signals a potential shift in Muneer Satter's stake or strategy concerning Aileron Therapeutics, which could influence the company's stock performance and corporate governance.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often indicate significant changes in a major shareholder's position or intentions, which can introduce volatility.

Key Players & Entities

• Muneer A. Satter (person) — Filing person
• Aileron Therapeutics, Inc. (company) — Subject company
• Satter Investment Management, LLC (company) — Associated entity

FAQ

Key Financial Figures

• $0.001 — ame of issuer) Common Stock, par value $0.001 (Title of class of securities) 00887A

Filing Documents

• ff3106565_13da5-aileron.htm (SC 13D/A) — 49KB
• 0000895345-24-000084.txt ( ) — 50KB

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer.

(a) of the Prior Filings is hereby deleted and replaced as follows

Item 5(a) of the Prior Filings is hereby deleted and replaced as follows: (a) Amount beneficially owned as of the date hereof: Amount beneficially owned: The Reporting Person beneficially owns an aggregate of 1,017,033 shares of Common Stock. The shares of Common Stock beneficially owned by the Reporting Person include (a) 51,253 shares of Common Stock that are held by Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares; (b) 61,547 shares of Common Stock that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares; (c) 717,666 shares of Common Stock that are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares, and (d) Warrants to purchase 186,567 shares of Common Stock held by SMTP and exercisable within sixty days of the date hereof, for which the Reporting Person has sole voting and dispositive power over all such Warrants and the underlying shares of Common Stock. Percent of class: In the aggregate the Reporting Person beneficially owns 1,017,033 shares of Common Stock, which amount represents 5.9% of the total number of shares of Common Stock outstanding. All percentages calculated in this Schedule 13D are based on an aggregate of 17,159,375 shares of Common Stock outstanding, comprised of (i) 4,885,733 shares of Common Stock that the Company reported as outstanding as of October 31, 2023 in the Merger 8-K filed with the SEC on October 31, 2023, plus (ii) 12,087 shares of Series X Non-Voting Convertible Preferred Stock automatically converted into 12,087,075 shares of Common Stock on March 5, 2024 as reported in the 8-K filed with the SEC on February 29, 2024, plus (iii) exercisable Warrants to purchase 186,567 shares of Common Stock held b

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: March 5, 2024 /s/ Muneer A. Satter Muneer A. Satter Page 4 of 4 Pages

View Full Filing

View this SC 13D/A filing on SEC EDGAR